Abstract
There is considerable evidence that pre-operative and post-operative anti-human leukocyte antigen (anti-HLA) antibodies are deleterious in thoracic transplantation. While debate continues in heart and lung transplantation on the role of and the diagnosis and treatment of antibody-mediated rejection (AMR), central to the discussion is our ability to detect anti-HLA antibodies. This perspective outlines the concerns elicited by new technology for detection of anti-HLA antibodies using solid-phase assays, and highlights the need for functional assays to further understand the clinical significance of these antibodies.
Original language | English (US) |
---|---|
Pages (from-to) | 1207-1209 |
Number of pages | 3 |
Journal | Journal of Heart and Lung Transplantation |
Volume | 29 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2010 |
Keywords
- anti-HLA antibody
- antibody-mediated rejection
- panel reactive antibodies
- solid-phase assays
- virtual crossmatch
ASJC Scopus subject areas
- Surgery
- Pulmonary and Respiratory Medicine
- Cardiology and Cardiovascular Medicine
- Transplantation